Bruker Swings to Q3 Loss on $96.5M Goodwill Impairment

TL;DR

**Bruker's Q3 loss driven by a massive goodwill impairment is a red flag; sell or hold off on buying until they clarify the underlying asset issues.**

AI Summary

Bruker Corporation reported a significant net loss of $59.6 million for the three months ended September 30, 2025, a stark contrast to the net income of $40.9 million in the same period of 2024. This downturn was primarily driven by a goodwill impairment charge of $96.5 million in Q3 2025, where no such charge existed in Q3 2024. Total revenue remained relatively flat, decreasing slightly to $860.5 million in Q3 2025 from $864.4 million in Q3 2024, with product revenue declining by $18.2 million and service revenue increasing by $14.3 million. Operating expenses surged to $431.2 million in Q3 2025 from $350.7 million in Q3 2024, largely due to the impairment charge. For the nine months ended September 30, 2025, the company recorded a net loss of $34.6 million, compared to a net income of $99.4 million in the prior year period. Cash and cash equivalents increased to $293.1 million as of September 30, 2025, from $183.4 million at December 31, 2024, partly due to proceeds from the issuance of Series A Mandatory Convertible Preferred Stock totaling $669.5 million. The company's total assets grew to $6,434.9 million from $5,806.7 million over the same period, while long-term debt decreased slightly to $1,984.2 million from $2,061.8 million.

Why It Matters

Bruker's swing to a net loss, primarily due to a substantial goodwill impairment charge, signals potential overvaluations of past acquisitions or a deterioration in the performance of certain business units. This directly impacts investor confidence, as it suggests a re-evaluation of future earnings potential and could lead to downward revisions in stock price targets. For employees, it might indicate a period of increased scrutiny on operational efficiency and potentially slower growth. Customers could see this as a sign of strategic shifts, though the core business of scientific instruments remains vital. In the competitive landscape, this impairment could weaken Bruker's position if rivals are demonstrating stronger organic growth or more successful integration of acquisitions.

Risk Assessment

Risk Level: high — The goodwill impairment charge of $96.5 million for the three months ended September 30, 2025, is a significant indicator of high risk, representing a substantial write-down of asset value. This charge directly contributed to a net loss of $59.6 million, a sharp decline from the $40.9 million net income in the prior year, demonstrating a material negative impact on profitability and potentially underlying business segment weakness.

Analyst Insight

Investors should scrutinize the specific segment or acquisition that led to the $96.5 million goodwill impairment. Await further clarification from management regarding the long-term outlook for the affected business unit and consider reducing exposure if the impairment signals systemic issues rather than a one-off adjustment.

Financial Highlights

debt To Equity

0.81

revenue

$860.5M

operating Margin

N/A

total Assets

$6,434.9M

total Debt

$1,984.2M

net Income

-$59.6M

eps

-$0.41

gross Margin

44.1%

cash Position

$293.1M

revenue Growth

-0.5%

Revenue Breakdown

Key Numbers

• $59.6M — Net Loss (Attributable to common shareholders for Q3 2025, a significant swing from $40.9M net income in Q3 2024.)
• $96.5M — Goodwill Impairment Charge (Recorded in Q3 2025, a primary driver of the net loss.)
• $860.5M — Total Revenue (For Q3 2025, a slight decrease from $864.4M in Q3 2024.)
• $34.6M — Nine-Month Net Loss (Attributable to common shareholders for the nine months ended September 30, 2025, compared to $99.4M net income in the prior year period.)
• $293.1M — Cash and Cash Equivalents (As of September 30, 2025, an increase from $183.4M at December 31, 2024.)
• $669.5M — Preferred Stock Proceeds (Net proceeds from the issuance of Series A Mandatory Convertible Preferred Stock in Q3 2025.)
• $1,984.2M — Long-Term Debt (As of September 30, 2025, a decrease from $2,061.8M at December 31, 2024.)
• $6,434.9M — Total Assets (As of September 30, 2025, an increase from $5,806.7M at December 31, 2024.)
• $0.41 — Basic EPS Loss (For Q3 2025, compared to $0.27 basic EPS income in Q3 2024.)

Key Players & Entities

• BRUKER CORPORATION (company) — registrant
• Nasdaq Global Select Market (regulator) — exchange for common and preferred stock
• $96.5 million (dollar_amount) — goodwill impairment charge
• $59.6 million (dollar_amount) — net loss attributable to Bruker Corporation common shareholders for Q3 2025
• $40.9 million (dollar_amount) — net income attributable to Bruker Corporation common shareholders for Q3 2024
• $860.5 million (dollar_amount) — total revenue for Q3 2025
• $864.4 million (dollar_amount) — total revenue for Q3 2024
• $669.5 million (dollar_amount) — proceeds from issuance of Series A Mandatory Convertible Preferred Stock
• $293.1 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $183.4 million (dollar_amount) — cash and cash equivalents as of December 31, 2024

FAQ

Risk Factors

• Goodwill Impairment [high — financial]: A significant goodwill impairment charge of $96.5 million was recorded in Q3 2025, directly contributing to the net loss of $59.6 million for the quarter. This contrasts with no such charge in Q3 2024, highlighting a potential overvaluation of past acquisitions or a decline in the expected future performance of acquired assets.
• Deteriorating Profitability [high — financial]: The company swung from a net income of $40.9 million in Q3 2024 to a net loss of $59.6 million in Q3 2025. For the nine months ended September 30, 2025, net loss was $34.6 million compared to a net income of $99.4 million in the prior year period, indicating a substantial decline in overall profitability.
• Rising Operating Expenses [medium — operational]: Operating expenses increased to $431.2 million in Q3 2025 from $350.7 million in Q3 2024, excluding the goodwill impairment charge. This increase, even before the impairment, suggests potential inefficiencies or increased investment in areas not immediately translating to revenue growth.
• Increased Leverage from Preferred Stock [medium — financial]: The issuance of $669.5 million in Series A Mandatory Convertible Preferred Stock in Q3 2025, while boosting cash, introduces future obligations and potential dilution. The balance sheet shows $692.6 million aggregate liquidation preference for this stock.
• Flat Revenue Performance [medium — market]: Total revenue remained nearly flat, decreasing slightly from $864.4 million in Q3 2024 to $860.5 million in Q3 2025. This lack of growth in a dynamic market could indicate competitive pressures or slowing demand for its products and services.

Industry Context

Bruker Corporation operates in the scientific instruments and life science tools market, a sector characterized by innovation and demand driven by research and development in areas like healthcare, diagnostics, and materials science. The industry is competitive, with companies focusing on advanced technologies and integrated solutions to capture market share. Trends include increasing demand for high-throughput screening, personalized medicine, and advanced analytical techniques.

Regulatory Implications

As a publicly traded company, Bruker is subject to SEC regulations and accounting standards, including those governing financial reporting and disclosures. The goodwill impairment charge and the issuance of convertible preferred stock require careful adherence to reporting requirements to ensure transparency for investors. Compliance with environmental, health, and safety regulations relevant to its manufacturing and product offerings is also critical.

What Investors Should Do

1. Monitor the impact of the goodwill impairment on future earnings and strategic decisions.
2. Analyze the sustainability of service revenue growth and its ability to offset product revenue declines.
3. Evaluate the financial implications of the Series A Mandatory Convertible Preferred Stock issuance.
4. Assess the company's ability to return to profitability and manage operating expenses.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported a net loss of $59.6 million, including a $96.5 million goodwill impairment charge. Total revenue was $860.5 million. Cash increased to $293.1 million.
• 2024-09-30: End of Q3 2024 — Reported a net income of $40.9 million with no goodwill impairment. Total revenue was $864.4 million.
• 2025-12-31: End of Fiscal Year 2024 — Cash and cash equivalents were $183.4 million, and total assets were $5,806.7 million. Long-term debt was $2,061.8 million.

Glossary

Goodwill Impairment Charge

A non-cash expense recognized when the carrying value of goodwill on a company's balance sheet exceeds its fair value, indicating that the acquired business is not performing as expected. (A $96.5 million charge in Q3 2025 significantly impacted net income, leading to a net loss.)

Mandatory Convertible Preferred Stock

A type of preferred stock that automatically converts into a specified number of common shares of the issuing company on a future date, or upon the occurrence of certain events. (Bruker issued $669.5 million in Series A Mandatory Convertible Preferred Stock, impacting its capital structure and future share count.)

Basic EPS Loss

The net loss per share attributable to common shareholders, calculated by dividing the net loss by the weighted-average number of outstanding common shares. (Bruker reported a basic EPS loss of $0.41 for Q3 2025, a negative swing from $0.27 EPS income in Q3 2024.)

Retained Earnings

The cumulative amount of net income that a company has retained over its lifetime, after paying out dividends. (Retained earnings decreased from $2,406.7 million at December 31, 2024, to $2,352.2 million at September 30, 2025, reflecting the net loss incurred.)

Year-Over-Year Comparison

Bruker Corporation's Q3 2025 results show a significant deterioration compared to Q3 2024. Total revenue saw a slight decrease of 0.5% to $860.5 million. The most striking change is the net loss of $59.6 million, a stark contrast to the $40.9 million net income in the prior year, primarily driven by a $96.5 million goodwill impairment charge. Operating expenses also increased substantially. While cash position improved to $293.1 million due to preferred stock issuance, the overall financial performance indicates increased risk and reduced profitability.

Key Financial Figures

• $0.01 — on which registered Common Stoc k, $0.01 par value per share BRKR Nasdaq Glo

Filing Documents

• brkr-20250930.htm (10-Q) — 6205KB
• brkr-ex31_1.htm (EX-31.1) — 18KB
• brkr-ex31_2.htm (EX-31.2) — 18KB
• brkr-ex32_1.htm (EX-32.1) — 18KB
• 0001193125-25-267049.txt ( ) — 24169KB
• brkr-20250930.xsd (EX-101.SCH) — 1973KB
• brkr-20250930_htm.xml (XML) — 6329KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 3:

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 51 Item 4:

Controls and Procedures

Controls and Procedures 51 Part II OTHER INFORMATION 51 Item 1:

Legal Proceedings

Legal Proceedings 51 Item 1A:

Risk Factors

Risk Factors 51 Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 53 Item 5: Other Information 54 Item 6: Exhibits 55

Signatures

Signatures 56 2 Table of Contents

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS BRUKER CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 293.1 $ 183.4 Accounts receivable, net 550.9 565.5 Inventories 1,196.6 1,067.8 Other current assets 310.0 236.5 Total current assets 2,350.6 2,053.2 Property, plant and equipment, net 746.7 669.3 Goodwill and intangible assets, net 2,468.8 2,419.8 Other long-term assets 868.8 664.4 Total assets $ 6,434.9 $ 5,806.7 LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of long-term debt and finance lease obligations $ 24.3 $ 32.5 Accounts payable 184.4 234.1 Deferred revenue and customer advances 455.4 438.2 Other current liabilities 604.0 576.5 Total current liabilities 1,268.1 1,281.3 Long-term debt 1,984.2 2,061.8 Other long-term liabilities 690.2 648.4 Redeemable noncontrolling interests 42.9 18.1 Shareholders' equity: Preferred stock, par value $ 0.01 ; Authorized - 5,000,000 shares Series A 6.375 % Mandatory Convertible; $ 250 per share liquidation preference or $ 692.6 million in the aggregate; Issued and outstanding - 2,760,000 shares (2024: nil ) — — Common stock, par value $ 0.01 ; Authorized - 260,000,000 shares Issued - 182,170,700 shares (2024: 182,456,831 ); Outstanding - 151,391,821 shares (2024: 151,677,952 ) 1.8 1.8 Treasury stock, at cost Purchased - 30,979,610 shares (2024: 30,778,879 ) ( 1,247.2 ) ( 1,237.2 ) Additional paid-in capital 1,404.3 713.4 Retained earnings 2,352.2 2,406.7 Accumulated other comprehensive loss, net of tax ( 79.2 ) ( 103.5 ) Total shareholders' equity attributable to Bruker Corporation 2,431.9 1,781.2 Noncontrolling interests in consolidated subsidiarie

View Full Filing

View this 10-Q filing on SEC EDGAR